Preclinical study of a biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC.
Seung Yeon OhYou Won LeeEun Ji LeeSeok-Young KimYoung Joon ParkSeong Gu HeoMi Ra YuMin Hee HongJohn O DaSilvaChristopher DalyByoung Chul ChoSun Min LimMi Ran YunPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Altogether, REGN5093-M114 is a promising candidate to overcome the challenges facing functional MET pathway blockade.